Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 6Specimen Handling 4Neoadjuvant Therapy 3Radiotherapy 2Chemotherapy, Adjuvant 2Biopsy 2Anastrozole 2trastuzumab biosimilar HLX02 1sargramostim 1exemestane 1UAB 30 1Trastuzumab 1Surgical Procedures, Operative 1Sulindac 1Polymerase Chain Reaction 1PF-05280014 1Ontruzant 1Omacor 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Lapatinib 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Immunoenzyme Techniques 1High-Energy Shock Waves 1HER2 peptide (369-377) 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fulvestrant 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Intraductal, Noninfiltrating × Omacor × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡